DARA BioSciences, Inc. – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 3 PAGES: 82

More Info
									   DARA BioSciences, Inc. – Product Pipeline Review –
                       H2 2011
                                                                                          Reference Code: GMDHC01762CDB

                                                                                                 Publication Date: NOV 2011




DARA BioSciences, Inc. – Product Pipeline Review – H2 2011                                  GMDHC01762CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
DARA BioSciences, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 4
      List of Figures .................................................................................................................................................................................................... 5
DARA BioSciences, Inc. Snapshot ........................................................................................................................................................................... 6
      DARA BioSciences, Inc. Overview ..................................................................................................................................................................... 6
      Key Information .................................................................................................................................................................................................. 6
      Key Facts ........................................................................................................................................................................................................... 6
DARA BioSciences, Inc. – Research and Development Overview ............................................................................................................................ 7
      Key Therapeutic Areas ....................................................................................................................................................................................... 7
DARA BioSciences, Inc. – Pipeline Review .............................................................................................................................................................. 9
      Pipeline Products by Stage of Development ....................................................................................................................................................... 9
      DARA BioSciences, Inc. – Pipeline Products Glance.........................................................................................................................................10
      DARA BioSciences, Inc. Clinical Stage Pipeline Products .................................................................................................................................10
            Phase II Products/Combination Treatment Modalities .................................................................................................................................10
      DARA BioSciences, Inc.–Early Stage Pipeline Products ...................................................................................................................................11
            Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................11
            Discovery Products/Combination Treatment Modalities ..............................................................................................................................12
DARA BioSciences, Inc. – Drug Profiles ..................................................................................................................................................................13
      DB160 ...............................................................................................................................................................................................................13
            Product Description ....................................................................................................................................................................................13
            Mechanism of Action...................................................................................................................................................................................13
            R&D Progress .............................................................................................................................................................................................13
      DB200 ...............................................................................................................................................................................................................14
            Product Description ....................................................................................................................................................................................14
            Mechanism of Action...................................................................................................................................................................................14
            R&D Progress .............................................................................................................................................................................................14
      DB900 ...............................................................................................................................................................................................................15
            Product Description ....................................................................................................................................................................................15
            Mechanism of Action...................................................................................................................................................................................15
            R&D Progress .............................................................................................................................................................................................15
      DB959 ...............................................................................................................................................................................................................16
            Product Description ....................................................................................................................................................................................16
            Mechanism of Action...................................................................................................................................................................................16
            R&D Progress .............................................................................................................................................................................................16
      KRN5500 ..........................................................................................................................................................................................................17
            Product Description ....................................................................................................................................................................................17
            Mechanism of Action...................................................................................................................................................................................17
            R&D Progress .............................................................................................................................................................................................17
DARA BioSciences, Inc. – Pipeline Analysis ............................................................................................................................................................18
      DARA BioSciences, Inc. – Pipeline Products by Therapeutic Class ...................................................................................................................18
      DARA BioSciences, Inc. - Pipeline Products By Target .....................................................................................................................................19
      DARA BioSciences, Inc. – Pipeline Products by Route of Administration ..........................................................................................................20
      DARA BioSciences, Inc. – Pipeline Products by Molecule Type ........................................................................................................................21
DARA BioSciences, Inc. – Recent Pipeline Updates...............................................................................................................................................22
DARA BioSciences, Inc. - Dormant Projects ............................................................................................................................................................24
DARA BioSciences, Inc. - Discontinued Pipeline Products ......................................................................................................................................25




DARA BioSciences, Inc. – Product Pipeline Review – H2 2011                                                                                                  GMDHC01762CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
DARA BioSciences, Inc. – Product Pipeline Review



     Discontinued Pipeline Product Profiles ..............................................................................................................................................................25
           PT-100........................................................................................................................................................................................................25
           PT-100 + Cisplatin ......................................................................................................................................................................................25
           Talabostat + Docetaxel ...............................................................................................................................................................................26
           Talabostat + Gemcitabine ...........................................................................................................................................................................26
           Talabostat + Pemetrexed Disodium ............................................................................................................................................................26
           Talabostat + Rituximab ...............................................................................................................................................................................27
DARA BioSciences, Inc. – Company Statement ......................................................................................................................................................28
DARA BioSciences, Inc. – Locations And Subsidiaries ............................................................................................................................................32
     Head Office .......................................................................................................................................................................................................32
     Other Locations & Subsidiaries .........................................................................................................................................................................32
Recent Developments .............................................................................................................................................................................................33
           Mar 30, 2009: DARA BioSciences Presents Abstracts For DB959 At American Diabetes Association Scientific Sessions ..........................33
           Mar 29, 2011: DARA Reports Promising Findings From Phase II Study Of KRN5500 at ADEPT ................................................................33
           Jun 28, 2011: DARA BioSciences Presents Positive Results Of Phase I Study For DB959 At American Diabetes Association Scientific
           Session.......................................................................................................................................................................................................34
           Apr 27, 2010: DARA Partners With Division Of Cancer Prevention, National Cancer Institute For Clinical Development Of KRN5500 ........35
           Mar 26, 2010: DARA BioSciences Initiates Phase I Clinical Study Of DB959 For Treatment Of Type 2 Diabetes .......................................35
           Feb 22, 2010: DARA BioSciences' Clinical Study Results For KRN5500 Selected For Presentation At CHI's Annual 'Targeting Pain with
           Novel Therapeutics" Meeting ......................................................................................................................................................................36
           Jun 21, 2011: DARA BioSciences To Present Positive Results Of DB959 Phase I Study At Upcoming 71st ADA Scientific Sessions ........36
           Apr 21, 2011: DARA To Present Results Of DB959 Phase I Study At 71st ADA Scientific Sessions ...........................................................37
           Aug 18, 2011: DARA BioSciences Receives Fast Track Designation From FDA For KRN5500 For Treatment Of Chemotherapy-Induced
           Neuropathic Pain In Patients With Cancer ..................................................................................................................................................37
           Sep 15, 2011: DARA BioSciences To Present Positive Results Of KRN5500 Phase II Study At 5th Annual Therapeutics Summit .............38
           Sep 15, 2009: DARA BioSciences Presents Phase 2a Study Results For KRN5500 At the "12th International Conference On The
           Mechanisms And Treatment Of Neuropathic Pain" Meeting ........................................................................................................................38
           Dec 14, 2010: DARA BioSciences Reports Positive Phase II Data Of KRN5500 In Neuropathic Pain .........................................................39
           Jul 14, 2009: DARA BioSciences Releases Promising Preclinical Data For DB959 For Type 2 Diabetes . .................................................39
           Oct 10, 2011: DARA BioSciences Announces KRN5500 Demonstrated Significant Decrease In Intensity Of Neuropathic Pain In Patients
         
								
To top